美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Leverage Shares 2X Long ENTG Daily ETF

6.18

+0.22063.70%

成交量：1,364

成交額：8,041.86

市值：15.45萬

市盈率：- -

高：6.18

開：6.18

低：6.18

收：5.96

52周最高：14.51

52周最低：4.60

股本：2.50萬

流通股本：2.50萬

量比：0.99

換手率：5.46%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

更多創新藥有望納入醫保報銷

創新生物製劑落地中國！雙適應症惠及重度哮喘與鼻息肉患者

泰適卓®雙適應症在華上市，為重度哮喘、慢性鼻竇炎伴鼻息肉患者提供生物製劑創新治療選擇

康諾亞-B(02162)：CM512(TSLP x IL-13雙抗)注射液用於慢性鼻竇炎伴鼻息肉患者的II期臨床試驗達到所有研究終點

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/hant/stock/ENTL"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ENTL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTL\",,,,,undefined,":{"symbol":"ENTL","market":"US","secType":"STK","nameCN":"Leverage Shares 2X Long ENTG Daily ETF","latestPrice":6.18,"timestamp":1789492782187,"preClose":5.9594,"halted":0,"volume":1364,"delay":0,"changeRate":0.03701714937745413,"floatShares":25000,"shares":25000,"eps":0,"marketStatus":"交易中","change":0.2206,"latestTime":"09-15 13:21:46 EDT","open":6.18,"high":6.18,"low":6.18,"amount":8041.86438,"amplitude":0,"askPrice":5.85,"askSize":2920,"bidPrice":5.81,"bidSize":1300,"shortable":0,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789502400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1422507600000,"exchange":"CBOE","adjPreClose":5.9594,"nav":7.17,"aum":179250,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":6.22,"preClose":5.9594,"latestTime":"09:26 EDT","volume":126,"amount":777.127932,"timestamp":1789478807422,"change":0.2606,"changeRate":0.043729,"amplitude":0.069084},"postHourTrading":{"tag":"盘后","latestPrice":6.27,"preClose":5.9594,"latestTime":"19:50 EDT","volume":166,"amount":1038.5664,"timestamp":1789429853610,"change":0.3106,"changeRate":0.052119,"amplitude":0.026848},"volumeRatio":0.990638},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ENTL\",,,,,undefined,":{"symbol":"ENTL","floatShares":25000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.990638,"shares":25000,"dividePrice":0,"high":6.18,"amplitude":0,"preClose":5.9594,"low":6.18,"week52Low":4.6027,"pbRate":"--","week52High":14.5091,"institutionHeld":0,"latestPrice":6.18,"committee":-0.383886,"eps":0,"divideRate":0,"volume":1364,"delay":0,"ttmEps":0,"open":6.18,"prevYearClose":12.45,"prevWeekClose":7.1498,"prevMonthClose":6.76,"prevQuarterClose":14,"fiveDayClose":7.29,"twentyDayClose":10.05},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ENTL\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ENTL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ENTL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ENTL\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664383252","title":"更多創新藥有望納入醫保報銷","url":"https://stock-news.laohu8.com/highlight/detail?id=2664383252","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664383252?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 10:20","pubTimestamp":1788488426,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["IBBQ","PSCH","BK1161","06978","BK4588","MEDX","159992","BK1574","ENTL","HART","IHI","LNGR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660484381","title":"創新生物製劑落地中國！雙適應症惠及重度哮喘與鼻息肉患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2660484381","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660484381?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 18:40","pubTimestamp":1786963204,"startTime":"0","endTime":"0","summary":"今天，阿斯利康宣布，泰适卓?（英文商品名：Tezspire?，通用名：特泽利尤单抗注射液）在中国正式获批上市。依托两项关键III期临床研究的积极成果，该药物在国内斩获双重适应症，可用于成人及12岁以上青少年重度哮喘的维持治疗，同时能够联合鼻用糖皮质激素，治疗经系统性糖皮质激素、手术治疗后仍无法有效控制病情的慢性鼻窦炎伴鼻息肉成人患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608173843332125.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608173843332125.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["07766","TSII","TSLZ","ELOL","TSLQ","TSLT","ENTL","TSLY","TSYY","TSLW","TSLR","CRSH","TSDD","TSL","TSLI","TESL","TSLP","TSLL","07366","09366","TLA","TEST","TSLS","TSLG","TSLO","09766"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660334481","title":"泰適卓®雙適應症在華上市，為重度哮喘、慢性鼻竇炎伴鼻息肉患者提供生物製劑創新治療選擇","url":"https://stock-news.laohu8.com/highlight/detail?id=2660334481","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660334481?lang=zh_tw&edition=fundamental","pubTime":"2026-08-17 16:21","pubTimestamp":1786954860,"startTime":"0","endTime":"0","summary":"特泽利尤单抗的上市，为慢性鼻窦炎伴鼻息肉患者带来了新的治疗选择，有望帮助他们实现长期疾病控制，改善生活质量。携双适应症在华上市，特泽利尤单抗有望充分释放上游炎症通路靶点的临床价值，进一步完善我们在哮喘领域从轻中度到重度的全病程疾病管理布局，加速哮喘治疗迈向'临床治愈'愿景，同时满足广大慢性鼻窦炎伴鼻息肉患者的未尽之需。其中，高达10%的哮喘患者为重度哮喘22,23。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5027377_ZH27377_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5027377_ZH27377_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0889565916.HKD","BK4007","LU2462157665.USD","LU0320765992.SGD","LU2237443465.HKD","BK4568","IE00B3T34201.USD","ENTL","LU0289739699.SGD","AZNH","LU0128525929.USD","AZN","LU1829250122.USD","LU2456880835.USD","LU2237443622.USD","LU2237443978.SGD","LU2236285917.USD","LU0109394709.USD","LU0310800379.SGD","IPOS","LU0708994859.HKD","LU2237443895.HKD","LU1267930573.SGD","BK4585","BK4588","LU2089984988.USD","LU2468319806.SGD","LU0029864427.USD","LU0058720904.USD","LU2237443382.USD","LU2237443549.SGD","LU0432979614.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605178","title":"康諾亞-B(02162)：CM512(TSLP x IL-13雙抗)注射液用於慢性鼻竇炎伴鼻息肉患者的II期臨床試驗達到所有研究終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605178","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658605178?lang=zh_tw&edition=fundamental","pubTime":"2026-08-10 08:09","pubTimestamp":1786320562,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康诺亚-B 发布公告，公司自主研发的1类新药CM512注射液治疗慢性鼻窦炎伴鼻息肉的II期临床研究已完成数据揭盲及初步统计分析。结果显示：1、CM512达到了全部研究终点，各剂量组疗效表现相当。CM512快速起效，给药第4周即可快速缩小鼻息肉同时显著改善鼻塞，并促进嗅觉功能恢复。基于此II期结果，公司正在快速启动CM512注射液治疗CRSwNP的临床III期研究，并明确300mg，半年给药一次为用药方案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477751.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","MDTX","IBBJ","BMED","IBBQ","BK1583","BK1587","ENTL","PSYK","02162","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ENTL\",params:#limit:6,delay:false,,,undefined,":[]}}